Eli A. Friedman

657 total citations
11 papers, 517 citations indexed

About

Eli A. Friedman is a scholar working on Nephrology, Surgery and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Eli A. Friedman has authored 11 papers receiving a total of 517 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Nephrology, 3 papers in Surgery and 3 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Eli A. Friedman's work include Blood properties and coagulation (2 papers), Pharmacological Effects and Toxicity Studies (2 papers) and Advanced Glycation End Products research (2 papers). Eli A. Friedman is often cited by papers focused on Blood properties and coagulation (2 papers), Pharmacological Effects and Toxicity Studies (2 papers) and Advanced Glycation End Products research (2 papers). Eli A. Friedman collaborates with scholars based in United States. Eli A. Friedman's co-authors include Kenneth Cartwright, Helen Vlassara, Richard Bucala, Roger A. Rodby, Anthony Cerami, Zenji Makita, Elliot J. Rayfield, Lorraine L. Thomas, Clinton D. Brown and Zhonghua Zhao and has published in prestigious journals such as Science, Kidney International and American Journal of Kidney Diseases.

In The Last Decade

Eli A. Friedman

11 papers receiving 492 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Eli A. Friedman United States	10	180	165	144	119	98	11	517
Rodolfo Russo Italy	14	104 0.6×	60 0.4×	236 1.6×	285 2.4×	70 0.7×	48	838
Manuel Macı́a Spain	11	84 0.5×	214 1.3×	52 0.4×	382 3.2×	68 0.7×	30	757
Yijuan Sun United States	14	38 0.2×	84 0.5×	94 0.7×	169 1.4×	108 1.1×	41	673
Hiromichi Gotoh Japan	15	55 0.3×	119 0.7×	75 0.5×	189 1.6×	31 0.3×	45	544
Stine E. Nielsen Denmark	12	134 0.7×	204 1.2×	39 0.3×	494 4.2×	60 0.6×	16	903
Jean‐Marc Hurot France	13	84 0.5×	90 0.5×	120 0.8×	320 2.7×	77 0.8×	30	590
Nigel N. Brown Australia	13	46 0.3×	115 0.7×	82 0.6×	63 0.5×	31 0.3×	19	768
Jesús Calviño Spain	12	30 0.2×	56 0.3×	118 0.8×	115 1.0×	73 0.7×	24	529
W. Lornoy Belgium	9	39 0.2×	46 0.3×	84 0.6×	290 2.4×	37 0.4×	17	572
Cuma Bülent Gul Türkiye	13	46 0.3×	87 0.5×	42 0.3×	89 0.7×	39 0.4×	51	479

Countries citing papers authored by Eli A. Friedman

Since Specialization

Citations

This map shows the geographic impact of Eli A. Friedman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eli A. Friedman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eli A. Friedman more than expected).

Fields of papers citing papers by Eli A. Friedman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eli A. Friedman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eli A. Friedman. The network helps show where Eli A. Friedman may publish in the future.

Co-authorship network of co-authors of Eli A. Friedman

This figure shows the co-authorship network connecting the top 25 collaborators of Eli A. Friedman. A scholar is included among the top collaborators of Eli A. Friedman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eli A. Friedman. Eli A. Friedman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

1.

Friedman, Eli A.. (2005). Consequences and management of hyperphosphatemia in patients with renal insufficiency. Kidney International. 67(95). S1–S7. 30 indexed citations

2.

Brown, Clinton D., et al.. (2004). Association of reduced red blood cell deformability and diabetic nephropathy. Kidney International. 67(1). 295–300. 112 indexed citations

3.

Ramirez, Sylvia, et al.. (2001). Funding ESRD care through charity: The paradigm of the National Kidney Foundation of Singapore. Seminars in Nephrology. 21(4). 411–418. 10 indexed citations

4.

Brown, Clinton D., et al.. (2001). Effects of erythropoietin and aminoguanidine on red blood cell deformability in diabetic azotemic and uremic patients. American Journal of Kidney Diseases. 38(6). 1414–1420. 16 indexed citations

5.

Friedman, Eli A., et al.. (1997). Aminoguanidine prolongs survival in azotemic-induced diabetic rats. American Journal of Kidney Diseases. 30(2). 253–259. 9 indexed citations

6.

Friedman, Eli A.. (1996). Bowel as a kidney substitute in renal failure. American Journal of Kidney Diseases. 28(6). 943–950. 20 indexed citations

7.

Ifudu, Onyekachi, et al.. (1995). Zidovudine Is Beneficial in Human Immunodeficiency Virus Associated Nephropathy. American Journal of Nephrology. 15(3). 217–221. 67 indexed citations

8.

Gloster, Elizabeth S., et al.. (1995). Penectomy in Diabetic Patients Undergoing Maintenance Dialysis. American Journal of Nephrology. 15(2). 152–156. 3 indexed citations

9.

Sumrani, Nabil, P. Daskalakis, Anne Marie V. Miles, et al.. (1993). Erythrocytosis After Renal Transplantation. ASAIO Journal. 39(1). 51–55. 20 indexed citations

10.

Makita, Zenji, Helen Vlassara, Elliot J. Rayfield, et al.. (1992). Hemoglobin-AGE: A Circulating Marker of Advanced Glycosylation. Science. 258(5082). 651–653. 218 indexed citations

11.

Nolph, Karl D., et al.. (1988). A survey of the NIH CAPD registry population with end-stage renal disease attributed to diabetic nephropathy. Journal of Diabetic Complications. 2(4). 227–232. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact